Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$110.20

3.46 (3.24%)

, CVS

CVS Health

$73.71

0.65 (0.89%)

20:25
11/05/18
11/05
20:25
11/05/18
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Eli Lilly (LLY), consensus $1.35... CVS Health (CVS), consensus $1.71... Becton Dickinson (BDX), consensus $2.93... Emerson Electric (EMR), consensus 89c... Air Products (APD), consensus $1.99... Archer-Daniels-Midland (ADM), consensus 83c... AmerisourceBergen (ABC), consensus $1.44... TransDigm Group (TDG), consensus $4.30... Henry Schein (HSIC), consensus $1.01... Expeditors (EXPD), consensus 79c... Ralph Lauren (RL), consensus $2.16... NIO Inc. (NIO), consensus (34c)... US Foods (USFD), consensus 51c... Premier (PINC), consensus 60c... ServiceMaster (SERV), consensus 77c.

LLY

Eli Lilly

$110.20

3.46 (3.24%)

CVS

CVS Health

$73.71

0.65 (0.89%)

BDX

Becton Dickinson

$237.26

1.65 (0.70%)

EMR

Emerson

$70.38

0.76 (1.09%)

APD

Air Products

$157.35

1.58 (1.01%)

ADM

Archer Daniels

$48.08

0.07 (0.15%)

ABC

AmerisourceBergen

$88.62

0.04 (0.05%)

TDG

TransDigm

$347.13

2.96 (0.86%)

HSIC

Henry Schein

$84.85

1.35 (1.62%)

EXPD

Expeditors

$68.96

-0.22 (-0.32%)

RL

Ralph Lauren

$136.69

2.76 (2.06%)

NIO

NIO Inc.

$6.67

0.175 (2.69%)

USFD

US Foods

$27.93

-1.265 (-4.33%)

PINC

Premier

$45.01

0.135 (0.30%)

SERV

ServiceMaster

$42.28

-0.6 (-1.40%)

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 27

    Nov

LLY Eli Lilly
$110.20

3.46 (3.24%)

10/31/18
10/31/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Electric (GE) upgraded to Buy from Neutral at UBS with analyst Steven Winoker saying he has conviction that new CEO Larry Culp can lead a turnaround of the business and his upside/downside analysis for shares now stands at a favorable 3:1 skew following the recent selloff. 2. Eli Lilly (LLY) upgraded to Neutral from Underperform at Credit Suisse. 3. Comerica (CMA) upgraded to Strong Buy from Outperform at Raymond James with analyst David Long saying the pullback in the sector provides more attractive risk/reward in Comerica shares and said its deposit base is relatively attractive given its high 52% composition of noninterest-bearing deposits, 87.5% loan/deposit ratio, and low 21% cumulative deposit beta. 4. Denny's (DENN) upgraded to Overweight from Equal Weight at Stephens with analyst Will Slabaugh saying the company's transition to a 95%-plus franchised model, and the improving return on invested capital that accompanies the transition, should "command a higher valuation." 5. ASML (ASML) upgraded to Buy from Hold at Santander. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/18
HCWC
10/31/18
NO CHANGE
Target $24
HCWC
Buy
Dicerna price target raised to $24 after Lilly, Alexion pacts at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Dicerna (DRNA) shares to $24 from $20 after the company announced collaborations with Eli Lilly (LLY) and Alexion Pharmaceuticals (ALXN). Arce views these partnerships as further strong validation of Dicerna's GalXC RNAi platform and keeps a Buy rating on the shares.
10/31/18
FBCO
10/31/18
UPGRADE
FBCO
Neutral
Eli Lilly upgraded to Neutral from Underperform at Credit Suisse
10/29/18
SBSH
10/29/18
NO CHANGE
Target $30
SBSH
Buy
Dicerna price target raised to $30 from $27 at Citi
Citi analyst Robyn Karnauskas said Dicerna's (DRNA) licensing and research collaboration with Eli Lilly (LLY) validates the former's RNAi platform and provides it with a meaningful cash infusion. The $200M upfront payment adds $3 to her discounted cash flow-derived price target, moving the target up to $30. Karnauskas keeps a Buy rating on Dicerna shares.
CVS CVS Health
$73.71

0.65 (0.89%)

10/25/18
WOLF
10/25/18
INITIATION
WOLF
Peer Perform
CVS Health initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Justin Lake assumed coverage on CVS Health with a Peer Perform citing moderating 2019 business momentum and limited growth visibility across the pharmacy and PBM businesses.
10/22/18
FBCO
10/22/18
NO CHANGE
Target $207
FBCO
Neutral
Aetna price target raised to $207 from $202 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Aetna (AET) to $207 from $202, while reiterating a Neutral rating on the shares. The analyst noted that the DOJ preliminary approved CVS' (CVS) acquisition of Aetna after the latter reached an agreement to sell its Medicare Part D drug plan business to WellCare Health Plans. Connecticut approved the CVS-AET deal October 17, and New York is expected to reach a decision after October 25, Rice adds. At this point, the analyst feels deal approval has a high probability of occurring, albeit the timing could be slightly later than CVS' outlook of early Q4 closing. Overall, Rice is putting a 90%-95% probability on the deal closure.
09/20/18
LEER
09/20/18
NO CHANGE
Target $250
LEER
Outperform
Cigna price target raised to $250 from $235 at Leerink
Leerink analyst Ana Gupte raised her price target on Outperform-rated Cigna (CI) to $250 from $235 following meetings with a panel of PBM and Specialty Rx specialists, which increased her bullishness on Cigna and Market Perform-rated Express Scripts (ESRX). In a research note to investors, Gupte says she also came away with raised confidence on the achiveability of the $4B annual drug cost savings from the Express Scripts switch by Anthem (ANTM) to IngenioRx in partnership with CVS (CVS). She adds that smaller independent PBMs still have niche opportunities with smaller regional third-party health plans, noting that Magellan Health (MGLN) is well positioned in this market, though loss of substantial business in Florida Seriously Mentally Ill is a headwind in Rx as well.
10/31/18
PIPR
10/31/18
DOWNGRADE
Target $206
PIPR
Neutral
Piper downgrades Aetna to Neutral on confidence of CVS deal closing
Piper Jaffray analyst Sarah James last night downgraded Aetna (AET) to Neutral from Overweight and lowered her price target for the shares to $206 from $212. The analyst is favorable on the fundamentals of Aetna's business and is confident the CVS Health (CVS) takeover will close given the recent Department of Justice approval. She believes Aetna shares will be range bound near the $206 per share takeout price.
BDX Becton Dickinson
$237.26

1.65 (0.70%)

10/15/18
LEHM
10/15/18
INITIATION
LEHM
Equal Weight
Becton Dickinson initiated with an Equal Weight at Barclays
Barclays analyst Kristen Stewart initiated Becton Dickinson with an Equal Weight rating and $278 price target.
10/09/18
SBSH
10/09/18
NO CHANGE
SBSH
Citi more selective on Medical Device stocks into Q3 results
Citi analyst Amit Hazan is "much more selective than usual" on Medical Device stocks into the Q3 earnings season. While easier comps should bring "strong and stable" Q3 organic sales growth, recent currency volatility will limit both earnings upside and guidance raises, Hazan tells investors in a research note. He sees only Boston Scientific (BSX) and Intuitive Surgical (ISRG) shares moving higher on earnings reports. The analyst expects volatility in both Becton Dickinson (BDX) and Varian Medical (VAR), but would be an "aggressive" buyer of the stocks on any post-earnings weakness. Hazan is also more cautious on names like Edwards Lifesciences (EW), Baxter (BAX), and Zimmer Biomet (ZBH) into the Q3 prints.
10/04/18
MSCO
10/04/18
NO CHANGE
Target $280
MSCO
Equal Weight
Becton Dickinson price target raised to $280 from $250 at Morgan Stanley
Morgan Stanley analyst David Lewis expects Becton Dickinson will guide FY19 revenue growth to 5%-6% during its upcoming Q4 earnings, which he believes "seems achievable if not conservative." Management is also likely to introduce revenue synergy guidance which should be higher, Lewis predicted. However, he thinks Becton's reported earnings guidance is likely to come in below the Street consensus. Lewis raised his price target on Becton Dickinson shares to $280 to reflect a roll forward to CY20 estimates and he keeps an Equal Weight rating on the stock.
09/10/18
ADAM
09/10/18
NO CHANGE
Target $80
ADAM
Buy
Quidel could draw interest from a larger company, says Canaccord
Canaccord analyst Mark Massaro remains positive on Quidel (QDEL) after hosting meetings with management. The analyst cited rising demand for its new products and he expects the company to continue to take market share from larger companies Alere (ABT) and Becton Dickinson (BDX). He also believes the company could draw interest from a larger company, like the bid Alere got from Abbott. Massaro reiterated his Buy rating and raised his price target to $80 from $78 on Quidel shares.
EMR Emerson
$70.38

0.76 (1.09%)

10/12/18
FBCO
10/12/18
INITIATION
FBCO
Outperform
EE, MI Sector initiated with Opportunistic View at Credit Suisse
Credit Suisse analyst John Walsh initiated the U.S. Electrical Equipment and Multi-Industry Sector with an Opportunistic View, telling investors in a research note that he believes at this point in the cycle stock appreciation will be driven by earnings growth and capital allocation. He is most positive on energy-related and non-residential end markets while cautious on Fossil Power markets. Specifically, Walsh initiated Allegion (ALLE), Eaton (ETN), Ingersoll-Rand (IR), Lennox (LII), 3M (MMM) and Xylem (XYL) with Outperform ratings, Acuity Brands (AYI), Emerson (EMR), Flowserve (FLS), Fortiv (FTV), GE (GE), Honeywell (HON) and Johnson Controls (JCI) with Neutral ratings and Rockwell Automation (ROK) with an Underperform rating.
10/18/18
JPMS
10/18/18
NO CHANGE
Target $90
JPMS
Overweight
JPMorgan's Tusa moves Emerson up to top pick after selloff
JPMorgan analyst Stephen Tusa says Emerson Electric moves up to being a top pick following the recent pullback in the shares. The analyst keeps an Overweight rating on the name with a $90 price target. Emerson Automation Solutions business is arguably one of the best fundamentally positioned single segment in the Electrical Equipment and Multi-Industry sector, Tusa tells investors in a research note. At 75% of the company, the analyst sees this segment being the "bulk of the story." Tusa also sees "tangible and legitimate reasons" as to why Emerson "should not only outperform organically near term, but also hold up significantly better than most in the sector in a tougher macro."
10/12/18
GDHS
10/12/18
INITIATION
Target $83
GDHS
Buy
Emerson initiated with a Buy at Gordon Haskett
Gordon Haskett analyst John Inch started Emerson Electric with a Buy rating and $83 price target.
10/12/18
FBCO
10/12/18
INITIATION
Target $78
FBCO
Neutral
Emerson initiated with a Neutral at Credit Suisse
Credit Suisse analyst John Walsh initiated Emerson Electric with a Neutral rating and $78 price target, telling investors in a research note that he sees organic sales growth sustaining a high-single digit rate driven by Automation Solutions growth as well as the successful integration of recent acquisitions.
APD Air Products
$157.35

1.58 (1.01%)

04/02/18
SBSH
04/02/18
NO CHANGE
SBSH
Buy
Citi finds FMC management most bullish on Mid-Atlantic tour
After meeting with senior management teams from Air Products (APD), FMC Corporation (FMC), PQ Group (PQG), Calyxt (CLXT) and AgroFresh Solutions (AGFS), Citi analyst P.J. Juvekar says FMC was the most bullish. FMC management highlighted strength in the company's Ag business and the ongoing integration from the DuPont acquisition, Juvekar tells investors in a research note. The analyst raised his estimates for FMC "across the board" on better Ag execution and calls the stock one of our top three ideas. On Air Products, the analyst is "getting more comfortable with the risk/reward of Chinese coal gasification projects." On PQ Group, Juvekar views the recent share pullback as overdone. The company delivered "two solid consecutive quarters" since the initial public offering and has made strides in reducing debt, the analyst contends.
09/24/18
BERN
09/24/18
INITIATION
Target $202
BERN
Outperform
Air Products initiated with an Outperform at Bernstein
Bernstein analyst Jonas Oxgaard started Air Products with an Outperform rating and $202 price target.
08/29/18
VERT
08/29/18
UPGRADE
VERT
Buy
Air Products upgraded to Buy from Hold at Vertical Research
05/16/18
SBSH
05/16/18
NO CHANGE
SBSH
Citi calls Axalta, Celanese top takeout candidates in Chemicals
While takeovers in the Chemicals space could slow after unprecedented consolidation in 2015-2017, Axalta Coating (AXTA) and Celanese (CE) represent the top buyout candidates in the U.S., Citi P.J. Juvekar tells investors in a research note. Top potential acquirers include Air Products (APD), PPG (PPG) and Albemarle (ALB), the analyst adds.
ADM Archer Daniels
$48.08

0.07 (0.15%)

05/02/18
MONN
05/02/18
UPGRADE
MONN
Neutral
Archer Daniels upgraded to Neutral from Sell at Monness Crespi
07/09/18
JPMS
07/09/18
UPGRADE
Target $48
JPMS
Neutral
Archer Daniels upgraded to Neutral ahead of Q2 results at JPMorgan
JPMorgan analyst Ann Duignan upgraded Archer Daniels Midland (ADM) to Neutral from Underweight and raised her price target for the shares to $48 from $42. The analyst keeps an Overweight rating on Bunge (BG) while lowering her price target for the shares to $82 from $90. Duignan expects Q2 to be "very strong" for Archer Daniels and "very challenging" for Bunge. The analyst, however, views Archer Daniels' stock as fairly valued and sees limited downside to Bunge's valuation in the near term. China's tariffs on U.S. soybeans have weighed on prices and driven record U.S. soy crush volume and margins, which is positive for ADM, Duignan tells investors in a research note. Meanwhile, trucker strikes in Brazil are likely to have weighed on Bunge's Q2 results with shutdowns impacting all segments, the analyst adds.
08/16/18
SPHN
08/16/18
NO CHANGE
Target $57
SPHN
Overweight
Archer Daniels price target raised to $57 after Brazilian deal at Stephens
Stephens analyst Farha Aslam noted that terms of Archer Daniels' deal to purchase Brazilian assets from Algar Agro were not disclosed, but she estimates the transaction to be valued at $200M-$300M. Aslam, who sees the deal strengthening Archer Daniels' positioning in the key agriculture market of Brazil, raised her price target on the stock to $57 from $52 and keeps an Overweight rating on Archer Daniels shares.
07/09/18
JPMS
07/09/18
UPGRADE
Target $48
JPMS
Neutral
Archer Daniels upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Ann Duignan upgraded Archer Daniels Midland to Neutral and raised her price target for the shares to $48 from $42 ahead of the company's Q2 results.
ABC AmerisourceBergen
$88.62

0.04 (0.05%)

07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
AmerisourceBergen downgraded to Neutral from Outperform at Baird
07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
07/20/18
07/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Philip Morris (PM) downgraded to Neutral from Overweight at JPMorgan and to Market Perform from Outperform at Cowen. 2. Skechers (SKX) downgraded to Neutral from Positive at Susquehanna and to Market Perform from Outperform at Wells Fargo. 3. McKesson (MCK), AmerisourceBergen (ABC), and Express Scripts (ESRX) downgraded to Neutral from Outperform at Baird. 4. Five Below (FIVE) downgraded to Neutral from Outperform at Credit Suisse with analyst Judah Frommer saying he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. 5. Yum China (YUMC) downgraded to Underperform from Neutral at BofA/Merrill with analyst Chen Luo saying he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/18
BARD
07/20/18
DOWNGRADE
BARD
Neutral
Express Scripts, AmerisourceBergen, McKesson cut to Neutral at Baird
As previously reported, Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC) and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against PBMs and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment, stating that visibility has deteriorated further across the supply chain.
TDG TransDigm
$347.13

2.96 (0.86%)

10/11/18
RHCO
10/11/18
NO CHANGE
Target $436
RHCO
Buy
TransDigm price target raised to $436 from $400 at SunTrust
SunTrust analyst Michael Ciarmoli raised his price target on TransDigm (TDG) to $436 and kept his Buy rating to reflect the impact of its Esterline (ESL) acquisition. The analyst notes that while the purchase multiple of 12.5-times his expected FY19 EBITDA "looks rich for a challenged asset", there is "ample runway for cost cutting opportunities". While Ciarmoli expectes some $500M-$600M in revenue to be divested to help finance the deal, he also sees it generating the "next leg up of stock appreciation".
10/11/18
10/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Huntington Ingalls (HII) downgraded to Sell from Neutral at Goldman Sachs with analyst Noah Poponak saying the company's pace of growth may not support current valuation levels. 2. Ferrari (RACE) downgraded to Hold from Buy at Jefferies with analyst Philippe Jean Houchois saying he re-based his expectations lower to reflect higher upfront investments and a lower quality of earnings as management's new strategy of less volume and more exclusivity takes hold. 3. Valero (VLO) downgraded to Hold from Buy at Tudor Pickering. 4. TransDigm (TDG) downgraded to Neutral from Outperform at Baird with analyst Peter Arment saying the Esterline (ESL) deal is a shift in the company's strategy in buying a "fixer-up asset" with significantly below average returns that will take time to improve. He believes it will be an overhang on the stock near-term. Arment maintained his $365 price target on TransDigm shares. 5. Tata Motors (TTM) downgraded to Hold from Buy at HSBC with analyst Amyn Pirani saying while the company's India business has surprised positively, Jaguar Land Rover's volumes have continued to decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/18
BARD
10/11/18
DOWNGRADE
Target $365
BARD
Neutral
TransDigm downgraded to Neutral after 'fixer-up' Esterline deal at Baird
As reported previously, Baird analyst Peter Arment downgraded TransDigm (TDG) to Neutral from Outperform. The analyst said the Esterline (ESL) deal is a shift in the company's strategy in buying a "fixer-up asset" with significantly below average returns that will take time to improve. He believes it will be an overhang on the stock near-term. Arment maintained his $365 price target on TransDigm shares.
10/11/18
10/11/18
UPGRADE
Target $122.5

Neutral
Esterline upgraded to Neutral on TransDigm pending acquisition at Credit Suisse
As previously reported, Credit Suisse analyst Robert Spingarn upgraded Esterline to Neutral from Underperform given pending acquisition by TransDigm (TDG). The analyst also raised his price target on Esterline's shares to $122.50 from $66.
HSIC Henry Schein
$84.85

1.35 (1.62%)

10/25/18
EDJN
10/25/18
DOWNGRADE
EDJN
Sell
Henry Schein downgraded to Sell from Hold at Edward Jones
08/08/18
08/08/18
DOWNGRADE
Target $40

Equal Weight
Morgan Stanley downgrades Dentsply Sirona to Equal Weight on limited visibility
As previously reported, Morgan Stanley analyst Steve Beuchaw downgraded Dentsply Sirona (XRAY) to Equal Weight from Overweight, estimating that its revenue and EPS growth were pressured by 1% and 2%, respectively, over the last two years by inventory reductions by Patterson Companies (PDCO). Additionally, modest organic growth continued into Q2, suggesting that the headwind from the loss of exclusivity with Patterson has not been offset as anticipated by Dentsply's new relationship with Henry Schein (HSIC), Beuchaw tells investors. Second half guidance confirms channel positioning remains a headwind, while the company's guidance cut reflects inventory pressures re-accelerating from both Patterson and Henry Schein, added the analyst, who cut his price target on Dentsply shares to $40 from $54.
08/07/18
BRRR
08/07/18
NO CHANGE
Target $92
BRRR
Outperform
Henry Schein target raised to $92 after 'encouraging' dental sales at Barrington
Barrington analyst Michael Petusky said Henry Schein's Q2 revenue of $3.33B exceeded his expectation and he was encouraged by the "very, very solid" performance of the dental business, adding that the company has a history of successfully adapting to changing markets. Following the earnings report, he reiterates an Outperform rating and increased his price target on Henry Schein shares to $92 from $88.
10/19/18
GSCO
10/19/18
INITIATION
Target $78
GSCO
Neutral
Henry Schein assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Nathan Rich assumed coverage of Henry Schein with a Neutral rating and $78 price target. While the analyst expects the company's above-market growth to continue, he thinks margin expansion in the range of its long-term guidance could be difficult to achieve.
EXPD Expeditors
$68.96

-0.22 (-0.32%)

11/13/17
GSCO
11/13/17
INITIATION
Target $59
GSCO
Neutral
Expeditors initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Matt Reustle initiated Expeditors of Washington with a Neutral rating and $59 price target. The analyst started the Rails sector with a Cautious coverage view and the Airfreight/Logistics sector with an Attractive coverage view.
11/08/17
UBSW
11/08/17
NO CHANGE
Target $56
UBSW
Sell
Expeditors earnings growth likely to remain muted, says UBS
UBS analyst Thomas Wadewitz noted Expeditors reported better than expected Q3 results on the strength of airfreight tonnage growth. He said it helped drive solid earnings growth, but gross margins continued to be pressured. The analyst believes earnings growth is likely to remain muted due to the potential cooling in air tons growth and pressure on air and ocean yields. Wadewitz maintained his Sell rating but raised his price target to $56 from $48 on Expeditors shares.
09/04/18
DBAB
09/04/18
INITIATION
Target $71
DBAB
Hold
Expeditors initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Seldon Clarke started Expeditors International of Washington with a Hold rating and $71 price target. The analyst sees limited upside in the shares following the recent outperformance.
RL Ralph Lauren
$136.69

2.76 (2.06%)

10/29/18
10/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with a Buy at Jefferies. 2. Ralph Lauren (RL) initiated with a Buy at Deutsche Bank. 3. Guardant Health (GH) initiated with an Outperform at Cowen and William Blair, an Overweight at JPMorgan, and a Neutral at BofA/Merrill. 4. Kodiak Sciences (KOD) initiated with a Buy at BofA/Merrill, as well as an Overweight at Barclays and Morgan Stanley. 5. Proteostasis (PTI) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/15/18
JPMS
10/15/18
UPGRADE
Target $150
JPMS
Overweight
JPMorgan upgrades Ralph Lauren to Overweight on recent pullback
JPMorgan analyst Matthew Boss upgraded Ralph Lauren to Overweight and raised his price target for the shares to $150 from $145. The recent pullback in the shares creates a "multi-year opportunity," Boss tells investors in a research note. The analyst sees Ralph Lauren's earnings growth profile accelerating to low-teens or a mid-teens total return profile for the next five years versus a 30% decline the past four years. Further, his fieldwork points to the company's North America same-store-sales inflecting positive in Q2 for the first time in three years.
10/15/18
10/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Outperform from In Line at Evercore ISI with analyst Matt McGinley citing lowered expectations on comps, a pullback in valuation relative to last year, and the more defensive nature of the business model. 2. PNC Financial (PNC) upgraded to Outperform from Market Perform at Bernstein and to Buy from Hold at Deutsche Bank. 3. Ralph Lauren (RL) upgraded to Overweight from Neutral at JPMorgan with analyst Matthew Boss saying the recent pullback in the shares creates a "multi-year opportunity." 4. Activision Blizzard (ATVI) upgraded to Overweight from Equal Weight at Barclays with analyst Ryan Gee saying his positive view is based on upside potential for Call of Duty digital revenue in 2019 from battle royale, as well as optimism for incremental product announcements at BlizzCon "fueling positive revisions" to consensus 2019 earnings estimates. 5. Lululemon (LULU) upgraded to Outperform from Neutral at Wedbush with analyst Jen Redding saying she has long viewed lululemon as an "impressive" growth story, with a best-in-class retail leadership team at the helm, and continues to see the company's cutting-edge data analytics and technology platforms on the forefront of wins in the years to come. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/29/18
DBAB
10/29/18
INITIATION
Target $149
DBAB
Buy
Ralph Lauren initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Paul Trussell started Ralph Lauren with a Buy rating and $149 price target. The analyst believes the brand's turnaround is in the early stages and views current share levels as proving a favorable entry point.
NIO NIO Inc.
$6.67

0.175 (2.69%)

10/09/18
JPMS
10/09/18
INITIATION
Target $7.5
JPMS
Neutral
NIO Inc. initiated with a Neutral at JPMorgan
JPMorgan analyst Nick Lai started NIO Inc. with a Neutral rating and $7.50 price target. The analyst wants to see a track record of execution before getting more constructive on the shares and adds that potential further capital raising could also be a risk before the company turns a profit in 2021.
10/22/18
FBCO
10/22/18
INITIATION
Target $12.6
FBCO
Outperform
Credit Suisse starts NIO Inc. with an Outperform rating, $12.60 price target
Credit Suisse analyst Bin Wang initated NIO Inc. with an Outperform rating and $12.60 price target, stating that the company has a well-establish premium branding in China and is a leader in smart electric vehicle technology. He estimates NIO's revenue will grow at a 192% CAGR to 2020 and sees the company achieving its first year of breakeven in 2021, when Wang assumes it will be able to produce 165,000 units.Target $12.60.
10/09/18
10/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Macquarie. 2. Tellurian (TELL) initiated with a Buy at BofA/Merrill. 3. NIO Inc. (NIO) initiated with a Neutral at JPMorgan and an Overweight at Morgan Stanley. 4. Eyenovia (EYEN) initiated with a Buy at H.C. Wainwright. 5. Garrett Motion (GTX) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/18
MSCO
10/09/18
INITIATION
Target $8.5
MSCO
Overweight
NIO Inc. initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jack Yeung initiated NIO Inc. with an Overweight rating and $8.50 price target, projecting a sales volume CAGR of 54.5% in 2017-22 for China's premium EV market and contending that NIO's price advantage over foreign competitors will allow it to penetrate the market. He notes that NIO's ES8, the company's first mass-produced model, has best-in-class specifications but a lower price, partly due to local manufacturing subsidies, the absence of customs duties and reduced taxes.
USFD US Foods
$27.93

-1.265 (-4.33%)

07/31/18
BOFA
07/31/18
NO CHANGE
BOFA
Buy
US Foods pullback overdone, says BofA/Merrill
BofA/Merrill analyst Marisa Sullivan said the pullback in US Foods following the disappointing Q2 report is overdone and headwinds are largely transitory. Sullivan believes the overall environment for independents remains healthy and US Foods remains well positioned for share gains with multiple levers to increase gross profits and opex improvement. The analyst rates US Foods a Buy with a $40 price target.
08/16/18
WELS
08/16/18
NO CHANGE
Target $44
WELS
Outperform
Performance Food Group should be bought on weakness at Wells Fargo
Wells Fargo analyst Edward Kelly lowered his price target for Performance Food Group (PFGC) to $44 from $46 after the company reported disappointing Q4 results on a "surprising" spike in labor investment. However, Overall, the analyst views the selloff as overdone and a compelling buying opportunity as the company's issues look temporary and very different from the execution problems at US Foods (USFD), and given visible path for better results and favorable industry backdrop. Kelly reiterates an Outperform rating on Performance Food Group shares.
10/22/18
BUCK
10/22/18
INITIATION
Target $32
BUCK
Neutral
US Foods initiated with a Neutral at Buckingham
Buckingham initiated US Foods with a Neutral $32 price target.
09/14/18
CLVD
09/14/18
NO CHANGE
CLVD
Neutral
US Foods Q3 sales likely below consensus, says Cleveland Research
Cleveland Research analyst Steve Gojak's checks indicate Q3 US Foods sales and case growth is trending below Street expectations. The analyst said overall sales trends do appear to have improved compared to trend driven by a recovery in the chain/non-commercial business.
PINC Premier
$45.01

0.135 (0.30%)

08/22/18
LEER
08/22/18
NO CHANGE
Target $55
LEER
Outperform
Premier price target raised to $55 from $45 at Leerink
Leerink analyst David Larsen raised his price target for Premier to $55 from $45, citing an "excellent" Q4 buoyed by return of performance services growth. The analyst reiterates an Outperform rating on the shares.
08/22/18
RAJA
08/22/18
NO CHANGE
Target $49
RAJA
Outperform
Premier price target raised to $49 following strong results at Raymond James
Raymond James analyst John Ransom raised Premier's price target to $49 from $37 following the "strong" Q4 report and FY19 guidance that was roughly in-line with consensus but did not contain share buybacks. The analyst said the one "blemish" on the call was the slowdown in forecasted GPO growth, which management attributed to conservative utilization.
08/22/18
RHCO
08/22/18
DOWNGRADE
Target $46
RHCO
Hold
Premier downgraded to Hold at SunTrust on valuation
As reported earlier, SunTrust analyst Sandy Draper downgraded Premier to Hold from Buy but raised his price target to $46 from $38. The analyst cites valuation as the primary driver of the rating change, saying the company is "finally getting the credit it deserves from the market for delivering solid results in a still tough health care IT market", rising over 40% since his last update in May. Draper adds that its valuation multiple of enterprise value to expected EBITDA has reached a 2-year peak of about 10.5-times, likely capping further upside in the stock price amid "stabilizing, but not accelerating fundamentals".
09/25/18
LEHM
09/25/18
INITIATION
Target $50
LEHM
Overweight
Premier initiated with an Overweight at Barclays
Barclays analyst Steve Valiquette started Premier with an Overweight rating and $50 price target. Despite a recent rally, the stock still trades at a "notable discount" to the company's five-year historical average, Valiquette tells investors in a research note. He expects the positive run rates from Premier's Q4 results to continue given the improving backdrop for Centers for Medicare and Medicaid Services reimbursement to the hospital industry "under Trump-appointed CMS leaders."
SERV ServiceMaster
$42.28

-0.6 (-1.40%)

10/02/18
OPCO
10/02/18
NO CHANGE
Target $47
OPCO
Outperform
ServiceMaster price target lowered to $47 from $65 at Oppenheimer
Oppenheimer analyst Ian Zaffino lowered his price target for ServiceMaster to $47 from $65 following AHS spinoff completion. ServiceMaster now operates the leading provider of termite/pest control services and a Franchise Services Group that includes Merry Maids and ServiceMaster Restore, he notes, adding that he believes Terminix offers significant upside potential. The analyst reiterates an Outperform rating on the shares.
10/03/18
STFL
10/03/18
NO CHANGE
Target $45
STFL
Buy
ServiceMaster price target raised to $45 from $40 at Stifel
Stifel analyst Michael Hoffman raised his price target on ServiceMaster (SERV) to $45 from $40 stating that better service, which results in higher retention, should lead to better margins and free cash flow conversion in the Pest Control segment while the Franchise Services Group should remain highly profitable and reliable. He also notes that ServiceMaster owns 19.9% of Frontdoor (FTDR) after the spinoff and that ownership should add $5 per share in value at the current market valuation of the newly-public company. Hoffman maintains a Buy rating on ServiceMaster shares.
10/10/18
NOMU
10/10/18
NO CHANGE
Target $53
NOMU
Buy
ServiceMaster price target raised to $53 from $48.20 at Nomura Instinet
Nomura Instinet analyst Dan Dolev raised his price target for ServiceMaster to $53 ahead of the company's Q3 results and keeps a Buy rating on the shares. The analyst expects warm temperatures, easing compares, and a minimal hurricane impact to non-franchised branches to help boost ServiceMaster's organic sales growth to 2%. He believes Q3 will likely prove to be a "watershed moment" for Terminix and reiterates a Buy rating on the shares.
10/02/18
10/02/18
DOWNGRADE
Target $42

Equal Weight
ServiceMaster downgraded to Equal Weight following spinoff at Morgan Stanley
As previously reported, Morgan Stanley analyst Toni Kaplan downgraded ServiceMaster (SERV) to Equal Weight from Overweight following the official spinoff of Frontdoor (FTDR), the company's previously wholly-owned home service plans business. She views the valuation of ServiceMaster, which now holds the Terminix business and Franchise Services Group, as fair given that the stock has re-rated significantly since the July 2017 announcement of the spinoff, Kaplan tells investors. She lowered her price target on ServiceMaster shares to $42 from $61.

TODAY'S FREE FLY STORIES

SYF

Synchrony

$33.97

0.48 (1.43%)

, SLB

Schlumberger

$31.90

-0.06 (-0.19%)

20:25
10/17/19
10/17
20:25
10/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

SYF

Synchrony

$33.97

0.48 (1.43%)

SLB

Schlumberger

$31.90

-0.06 (-0.19%)

AXP

American Express

$119.17

1.76 (1.50%)

KO

Coca-Cola

$53.80

0.31 (0.58%)

STT

State Street

$59.71

0.57 (0.96%)

CFG

Citizens Financial

$35.01

-0.12 (-0.34%)

KSU

Kansas City Southern

$135.33

1.04 (0.77%)

GNTX

Gentex

$27.57

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 27

    Oct

  • 04

    Nov

  • 13

    Nov

  • 06

    Dec

PLSE

Pulse Biosciences

$14.52

0.525 (3.75%)

20:10
10/17/19
10/17
20:10
10/17/19
20:10
Hot Stocks
Pulse Biosciences to present data from studies of nano-pulse stimulation at ASDS »

Pulse Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TW

Tradeweb Markets

$43.20

0.87 (2.06%)

19:50
10/17/19
10/17
19:50
10/17/19
19:50
Syndicate
Tradeweb Markets 17.29M share Secondary priced at $42.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

SWDAF

Software AG

$0.00

(0.00%)

19:33
10/17/19
10/17
19:33
10/17/19
19:33
Upgrade
Software AG rating change at Goldman Sachs »

Software AG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.43

-0.22 (-1.50%)

18:57
10/17/19
10/17
18:57
10/17/19
18:57
Hot Stocks
Petrobras reports Q3 production 2.878M boepd, up 9.3% »

Petrobras said it posted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

MRTN

Marten Transport

$21.52

0.31 (1.46%)

, ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

18:49
10/17/19
10/17
18:49
10/17/19
18:49
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MRTN

Marten Transport

$21.52

0.31 (1.46%)

ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

ETFC

E-Trade

$39.04

0.02 (0.05%)

WAL

Western Alliance

$46.24

0.53 (1.16%)

TEAM

Atlassian

$122.43

-1.91 (-1.54%)

PRTK

Paratek Pharmaceuticals

$3.46

0.05 (1.47%)

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

EXPO

Exponent

$70.82

1.34 (1.93%)

WDFC

WD-40

$182.75

2.41 (1.34%)

VICR

Vicor Corporation

$32.78

1.16 (3.67%)

OZK

Bank OZK

$28.32

0.03 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 22

    Nov

ARWR

Arrowhead

$36.61

2.11 (6.12%)

, AMGN

Amgen

$203.60

0.32 (0.16%)

18:43
10/17/19
10/17
18:43
10/17/19
18:43
Hot Stocks
Arrowhead CEO: We can silence a single gene »

In an interview on…

ARWR

Arrowhead

$36.61

2.11 (6.12%)

AMGN

Amgen

$203.60

0.32 (0.16%)

JNJ

Johnson & Johnson

$136.20

1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

SXT

Sensient

$66.57

0.4 (0.60%)

18:32
10/17/19
10/17
18:32
10/17/19
18:32
Hot Stocks
Sensient raises quarterly dividend 8.3% to 39c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

T

AT&T

$37.82

0.03 (0.08%)

18:31
10/17/19
10/17
18:31
10/17/19
18:31
Periodicals
HBO Max to stream Studio Ghibli films, Reuters says »

AT&T's upcoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

OMAB

OMA

$52.10

0.47 (0.91%)

18:19
10/17/19
10/17
18:19
10/17/19
18:19
Earnings
OMA reports Q3 net income MXN858M vs. MXN725M last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

MAR

Marriott

$120.57

-0.55 (-0.45%)

18:13
10/17/19
10/17
18:13
10/17/19
18:13
Periodicals
Marriott near deal for Elegant Hotels valued up to GBP1 / shr, Bloomberg says »

The report states that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

SPY

SPDR S&P 500 ETF Trust

$299.19

0.78 (0.26%)

, SPX

S&P 500

$0.00

(0.00%)

18:08
10/17/19
10/17
18:08
10/17/19
18:08
General news
NY Fed's Williams Condition in money markets highly volatile over past month »

Williams says:…

SPY

SPDR S&P 500 ETF Trust

$299.19

0.78 (0.26%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.20

-0.45 (-1.23%)

17:47
10/17/19
10/17
17:47
10/17/19
17:47
Periodicals
GM strike to continue until deal with UAW is ratified, WSJ says »

United Auto Workers union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.82

0.03 (0.08%)

17:37
10/17/19
10/17
17:37
10/17/19
17:37
Periodicals
AT&T, Elliott Management in talks to resolve activist campaign, WSJ reports »

AT&T is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

WAL

Western Alliance

$46.24

0.53 (1.16%)

17:27
10/17/19
10/17
17:27
10/17/19
17:27
Earnings
Western Alliance reports Q3 EPS $1.24, consensus $1.19 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 30

    Oct

  • 31

    Oct

  • 06

    Nov

RNLSY

Renault

$0.00

(0.00%)

17:25
10/17/19
10/17
17:25
10/17/19
17:25
Downgrade
Renault rating change at Deutsche Bank »

Renault downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$19.10

0.63 (3.41%)

17:24
10/17/19
10/17
17:24
10/17/19
17:24
Hot Stocks
Park West Management reports 5.1% passive stake in Lovesac »

Park West Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

T

AT&T

$37.82

0.03 (0.08%)

17:24
10/17/19
10/17
17:24
10/17/19
17:24
Periodicals
Breaking Periodicals news story on AT&T »

AT&T in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 18

    Nov

  • 19

    Nov

ATVI

Activision Blizzard

$55.60

0.01 (0.02%)

17:16
10/17/19
10/17
17:16
10/17/19
17:16
Hot Stocks
Activision says Call of Duty to get 'battle pass' feature, 'not loot box system' »

Activision's Call of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 07

    Nov

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:11
10/17/19
10/17
17:11
10/17/19
17:11
Hot Stocks
Brandywine Realty sees FY19 year-end core occupancy at 94%-95% »

Also sees FY20 year-end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:10
10/17/19
10/17
17:10
10/17/19
17:10
Hot Stocks
Brandywine Realty reports Q3 same-store net operating income up 0.6% »

Reports Q3 occupancy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:09
10/17/19
10/17
17:09
10/17/19
17:09
Earnings
Brandywine Realty sees FY20 initial FFO $1.41-$1.51, consensus $1.46 »

Sees FY20 same-store net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

17:08
10/17/19
10/17
17:08
10/17/19
17:08
Earnings
Gildan Activewear cuts FY19 adj. EPS view to $1.65-$1.70 from $1.95-$2.00 »

Consensus $1.97. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:07
10/17/19
10/17
17:07
10/17/19
17:07
Earnings
Brandywine Realty narrows FY19 FFO guidance to $1.41-$1.43 from $1.40-$1.44 

Consensus $1.42.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

17:07
10/17/19
10/17
17:07
10/17/19
17:07
Earnings
Brandywine Realty reports Q3 FFO 36c, consensus 36c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.